Lymphoma and CLL highlights of the ASH 2025

Catherine S. Diefenbach discusses the lymphoma and CLL highlights at the American Society of Hematology's 67th Annual Meeting.

Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

Matthew S. Davids discusses the available research guiding the selection of therapy for patients with chronic lymphocytic leukemia at the American Society of Hematology's 67th Annual Meeting.

Novelties in Acute Myeloid Leukemia at ASH2025

Mark Levis discusses the novelties in acute myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.

What's new in myeloma?

Enrique Ocio discusses what's new in multiple myeloma treatement at the American Society of Hematology's 67th Annual Meeting.

Azacitidine–Venetoclax Combination Outperforms Standard Care in Acute Myeloid Leukemia Patients Eligible for Intensive Chemotherapy

Amir Fathi discusses the results from a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.

Symptom-based progression-free survival as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the ALPINE trial

Jennifer R. Brown explains the results from the ALPINE trial at the American Society of Hematology's 67th Annual Meeting.

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Jesse Tettero discusses the results from the HARMONY Alliance study at the American Society of Hematology's 67th Annual Meeting.

Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL

Anand A. Patel discusses the primary efficacy analysis of a Phase II study investigating tyrosine kinase inhibitor and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukemia at the American Society of Hematology's 67th Annual Meeting.

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

Jennifer Woyach discusses the noncovalent BTK inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with CLL or SLL, according to findings from a randomized phase III trial presented at the American Society of Hematology's 67th Annual Meeting.

Quadruplet Therapy in Multiple Myeloma

Rahul Banerjee discusses the quadruplet therapy in multiple myeloma at the American Society of Hematology's 67th Annual Meeting.

Novelties in Diffuse Large B-cell Lymphoma at ASH2025

Joshua Brody discusses the novelties in diffuse large B-cell lymphoma at the American Society of Hematology's 67th Annual Meeting.

Breakthrough in the treatment of Multiple Myeloma

Xavier Leleu explains the breakthrough in the treatment of multiple myeloma at the American Society of Hematology's 67th Annual Meeting.

Diagnosis and Management of Cold Agglutinin Disease

Sigbjorn Berentsen discusses the diagnosis and management of cold agglutinin disease at the American Society of Hematology's 67th Annual Meeting.

Multiple Myeloma Highlights from ASH 2025

Paul G Richardson discusses multiple myeloma highlights at the American Society of Hematology's 67th Annual Meeting.

COBRA trial and other novelties in multiple myeloma at ASH 2025

Andrzej Jakubowiak discusses the COBRA trial and other novelties in multiple myeloma at the American Society of Hematology's 67th Annual Meeting.

Myelodysplastic Syndrome Highlights from ASH 2025

Mikkael A. Sekeres discusses the state of the art treatment in myelodysplastic syndrome at the American Society of Hematology's 67th Annual Meeting.